Alector, Inc.

NASDAQ:ALEC

Biotechnology

Healthcare
$2.56 +5.13%

+$0.08 today

Market cap
$381.13M
Beta
0.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.13
52W Low $1.09High $3.40

Volume 1.27M

Average 0.65M

ALEC Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Alector, Inc.NASDAQ: ALEC

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to -99.2%

Gross margin was -99.2% in Q1 FY2026, up 716.4 pp from a year earlier. On a trailing-twelve-month basis it was -61.2%, down 68.0 pp year over year. Over 3 fiscal years it narrowed by 45.9 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-99.2%-199.2 pp QoQ
Last fiscal yearDec 2025
54.1%+139.0 pp YoY
LTMMar 2026
-61.2%-68.0 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+716.4 pp——
1 year+139.0 pp——
3 years-45.9 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
54.1%
Year-over-year change
+139.0pp

Gross Margin vs competitors

How ALEC compares with its peers on the latest reported figures

  • ALEC's LTM Mar 2026 gross margin of -61.2% is the 2nd highest of the 3 companies compared; the peer median is -183.1%.
  • Its year-over-year change of -68.0 pp is the lowest of 3, against a peer median of +66.5 pp.
  • Over three fiscal years its change of -45.9 pp compares with a peer median of -89.9 pp.
ALEC Competitors Peer median
Gross Margin for ALEC and competitors
Company Period LTM level YoY 3-year change
IRDOpus Genetics, Inc.LTM Mar 202649.6% +6.6 pp+0.0 pp
ALECAlector, Inc.LTM Mar 2026-61.2% -68.0 pp-45.9 pp
FATEFate Therapeutics, Inc.LTM Mar 2026-415.8% +126.5 pp-179.8 pp
VORVor Biopharma Inc.FY2025— ——
PEPGPepGen Inc.FY2025— ——
MOLNMolecular Partners AGFY2025— ——
NKTXNkarta, Inc.FY2025— ——
CRBPCorbus Pharmaceuticals Holdings, Inc.FY2025— ——
ABOSAcumen Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding ALEC) -183.1%+66.5 pp-89.9 pp

Competitors are the stored peer set for ALEC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue207.09M133.62M97.06M100.56M21.05M
Cost of Revenue189.41M08.85M185.94M9.66M
Gross Profit17.68M133.62M88.21M(85.38M)11.38M
Gross Margin8.5%100.0%90.9%-84.9%54.1%
Research & Development189.41M210.42M192.12M209.24M123.07M
Selling, General & Admin55.04M61.03M56.69M57.41M53.99M
Operating Expenses55.04M271.45M239.95M59.62M157.19M
Depreciation & Amortization8.32M8.47M8.85M8.84M9.66M
EBITDA(28.01M)(121.58M)(116.33M)(110.08M)(133.1M)
EBITDA Margin-13.5%-91.0%-119.9%-109.5%-632.5%
Operating Income(37.36M)(137.83M)(151.74M)(145M)(145.81M)
Operating Margin-18.0%-103.2%-156.3%-144.2%-692.8%
Interest Income00000
Interest Expense00000
Other Income / Expenses1.03M7.78M26.56M26.08M3.05M
Income Before Tax(36.33M)(130.06M)(125.18M)(118.92M)(142.76M)
Pre-Tax Margin-17.5%-97.3%-129.0%-118.3%-678.4%
Income Tax Expense03.25M5.21M128K168K
Net Income(36.33M)(133.31M)(130.39M)(119.05M)(142.93M)
Net Margin-17.5%-99.8%-134.3%-118.4%-679.2%
EPS (Basic)(0.45)(1.62)(1.56)(1.23)(1.39)
EPS (Diluted)(0.45)(1.62)(1.56)(1.23)(1.39)
Weighted Avg Shares80.42M82.47M83.73M96.59M103M
Weighted Avg Shares (Diluted)80.42M82.47M83.73M96.59M103M

Alector, Inc.

NASDAQ:ALEC

Intrinsic Alpha fair value

Locked

Current Price

$2.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.